Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. ENT (Paediatric)
  6. Sialorrhoea (drooling) in children (1187)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Sialorrhoea (drooling) in children (1187)

Warning

Objectives

This document is intended to provide background information and general guidance for GPs, community paediatricians, palliative care doctors and professionals in acute paediatric medicine who are caring for children who drool saliva.  It is based on current practice, an extensive review of the published literature (available on request from the authors) and on the following NICE guidance documents: NG62 Cerebral palsy in under 25s: assessment and management and ES5 Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide.

Background

Drooling is normal in infants and typically stops by age 15-18 months, however is considered pathologic if present after 4 years.1

Sialorrhoea (chronic pathological drooling) is an unintentional loss of saliva from the mouth, the primary cause being neuromuscular dysfunction but other causes include hypersecretion and sensory or anatomic dysfunction1.  It is a common problem in children with neurodisabilities such as cerebral palsy where it can impact 22-40% of children2.

Sialorrhoea results in a number of clinical and psychosocial complications and has a significant negative impact on quality of life for both the patient and caregiver3. Physical complications include maceration of the skin with secondary infection, odour, dehydration, speech disturbance and interference with feeding2. Psychosocial complications include isolation, barriers to education, increased dependency and level of care and decreased self-esteem3.

Drooling is also a risk factor for aspiration, which can cause respiratory illness owing to bacteria in the aspirate or chronic inflammatory responses in the lungs4. Respiratory illness is the leading cause of hospitalisations and death in young people with cerebral palsy4 and 25% of CP patients of severity 4-5 GMFCS have chronic respiratory problems5.

Aspiration often occurs without obvious coughing or choking, therefore chronic aspiration of saliva might not be diagnosed prior to development of significant lung injury6.

The management of sialorrhoea is best accomplished with a multidisciplinary team approach3.

The severity of drooling can be assessed using the modified Teacher’s Drooling Scale (mTDS) or the Drooling Impact Scale (DIS).

Assessment

Ask about aspiration

Ask about coughing and choking on fluids and recurrent chest infections.  Aspiration requires early aggressive management to preserve lung function.

Action: Consider Speech and Language Therapy (SLT) clinical swallow assessment and videofluoroscopy.

Ask about salivary stimulants

Most children who drool do so because they have poor oral motor control and/or sensory awareness rather than because there is too much saliva. Genuine hypersalivation does occasionally occur. Saliva may be stimulated by certain drugs, including the benzodiazepine group particularly nitrazepam, and also by habitual finger-chewing, gastro-oesophageal reflux and dental caries.

Action: Check medications to exclude medication-induced hypersalivation. Consider deferring specific treatment of drooling if a child is being weaned off nitrazepam as it may improve once they are off the drug. Reflux, dental caries and finger chewing should be addressed on their own merits.

Ask about (and examine for) open-mouth posture

Children who habitually sit with their mouths open will be more prone to drool. Nasal obstruction (adenoid hypertrophy, allergic rhinitis) should be specifically examined for and treated. Dental malocclusion is another important cause of open-mouth posture, but orthodontic treatment may have to wait until the permanent dentition have erupted. Many children with neurodevelopmental disorders will have an open mouth posture because of poor muscle tone.

Action: Consider a trial of topical nasal steroids, non-sedating antihistamines or saline nasal douching for nasal obstruction. ENT referral may be required for adenoidectomy. Orthodontic advice should be sought for malocclusion.

Address the child’s posture

This is particularly a problem for children who are wheelchair users. If they are habitually sitting forward in the chair then drooling will be exacerbated because a stable body posture is necessary for development of independent movement of the jaw, lips and tongue and therefore ability to control saliva. Improving their position in the chair can make a huge difference to day-to-day symptoms. Equally, constructing a small wooden riser for the desk can allow them to use a computer or writing materials in an upright position rather than leaning over and this can also be beneficial. Be aware that some posture changes may increase the risk of aspiration.

Action: Consider liaising with the chair provider, physiotherapists and occupational therapists about seating position

Ask about speech and chewing

There is a small group of children with specific oral motor control issues in the absence of other major developmental delay. They may have difficulty chewing solid food and may even resort to moving food around their mouth with a finger. They may have indistinct speech due to poor articulation. We might label them as having an oral motor (or verbal) dyspraxia.

Action: SLT referral for assessment is the first step, but drugs, botulinum toxin injections and surgery may occasionally be justified.

Some children just require reassurance

Drooling is not uncommon in boys of 3-5 years and it is usually a self-limiting phenomenon that reflects their lack of social awareness. In the absence of any exacerbating factors as mentioned above, simple reassurance is reasonable in the first instance.

Consider SLT referral

Children who drool frequently enough that their face is always wet need to experience the contrast with dryness that would allow them to develop the inner choice to swallow. A constantly wet face from drooling reduces the sensory cues needed to trigger a swallow. With young children, who are otherwise developing normally, developing the concept of wet versus dry is often a first step in addressing drooling. Any behavioural approach involves teaching the child to recognise the feeling of wetness and be able to either swallow more frequently or wipe the saliva from the lips and chin. It is helpful to put in place reminders for them, such as a cue or a reward. It is also useful to teach “swallow and wipe” together because the mouth is cleared of saliva with each wipe. Wearing towelling wrist bands, may be helpful in enabling a child to keep clean and dry. They may also serve as a visual cue to remind the child to swallow.

For children who may not comply or understand the purpose of more specific oral motor exercises to develop jaw and lip control then a more functional approach to therapy may be more appropriate, e.g. graded straw drinking using lips alone. This skill can be developed by altering the variables of straw diameter / length and thickness of liquid. Graded blowing games, e.g. blowing bubbles/ candles to musical instruments (mouth organ to trumpets) may also be tried.

When drooling problems are more chronic then direct intervention to address oral motor control and/ or oral sensory awareness should be introduced. Oral facial treatments including specific techniques such as ‘Brushing and Icing’ are designed to improve oral sensory awareness. Improved sensory awareness will influence motor responses, e.g. swallowing in response to increases in saliva. Both brushing and icing are very stimulating and should be used with caution on young children and should not be used with children under the age of three years. This technique works best with children who have low postural tone and are orally hyposensitive. It is a technique that should be introduced by a speech and language therapist.

As stated, a stable aligned head and body posture is necessary for development of independent movement of the jaw, lips and tongue. Jaw stability is essential for the acquisition of lip closure and must be achieved before you can work on establishing dissociation of the jaw from the lips or tongue. When jaw control is established then therapy can address the development of lip control to increase awareness, placement, strength and memory for lip closure.

Success of all such strategies to address drooling is dependent on a number of factors, including level of cognition and compliance of the child and co-operation of key persons in the child’s life in helping to implement strategies in a regular routine way.

Action: Consider SLT referral for children who have an adequate level of comprehension/ co-operation and motivation to change behaviour.

Drug Treatments

Anticholinergic medications are widely used. All work by reducing saliva flow but the thick, sticky saliva produced can be troublesome in itself. Other common side effects include blurred vision, constipation, urinary retention, heatstroke in hot weather and behaviour changes and parents need to be warned to stop the drug if these occur.

Any attempt to reduce the amount of saliva (whether by means of drugs, botulinum toxin injections or surgery) puts the teeth at risk of decay. All children should see their dentist regularly for check-ups and fissure seals, and should brush twice a day with a fluoride toothpaste. Dry brushing and use of low foaming toothpaste products are recommended for those children who are nil by mouth. You may wish to discuss with a speech and language therapist how best to implement this intervention.

Action: Consider anticholinergics for children with persistent symptoms, particularly those for whom SLT interventions are unsuccessful or inappropriate. Parents must be warned of potential side effects.

Glycopyrronium Bromide

First Line – Sialanar

  • Sialanar is a brand licensed for chronic pathological drooling in children and adolescents aged 3 years and older with chronic neurological disorders.
  • Prescribe as ‘Sialanar/glycopyrronium bromide 400 micrograms/ml’
  • Sialanar is sugar and sorbitol free, therefore suitable for ketogenic diets and has a raspberry flavour
  • The dose for Sialanar is7:
    • Start at 16 micrograms/kg glycopyrronium bromide TDS, increasing in steps of 16micrograms/kg TDS every 5-7 days according to response. Maximum dose is 80 micrograms/kg TDS (maximum 2.4mg/dose).
    • The dose is started low and titrated upwards at weekly intervals according to effect, to balance efficacy with tolerability.
    • Dosing table is available below or at https://www.proveca.com/products/sialanar/dose-calculator/

Dosing table for Sialanar

Note:  both µg and mg refer to glycopyrronium bromide

*maximum individual dose for weight range

  • It can be administered orally or via feeding tube
  • Severe renal impairment is a contraindication for this medication and a revised treatment algorithm for children with mild to moderate renal impairment is available within Sialanar’s SmPC
  • If existing glycopyrronium patients are switched to Sialanar ensure that the dose is reviewed and the patient/carer is informed of the new volume in mls that needs to be given.
  • Glycopyrronium has a limited ability to cross the blood-brain barrier7 and therefore has fewer central side effects (drowsiness, sleep disturbance, and effects on seizure control) than hyoscine or trihexyphenidyl.
  • Glycopyrronium has demonstrated lower rates of side effects and treatment cessation vs. hyoscine2,8

BNFC guidance on glycopyrronium bromide.9

Glycopyrronium bromide oral solutions are not interchangeable on a microgram-for-microgram basis due to differences in bioavailability.9

  • Sialanar oral solution has approximately 25% higher bioavailability and therefore equivalent doses will be lower than for tablets and generic oral solutions. Sialanar oral solution contains 400 micrograms/mL of glycopyrronium bromide which is equivalent to 320 micrograms/mL of glycopyrronium.
  • The prescriber should state the specific branded or generic oral preparation to be used; care should be taken if switching between oral preparations and dosing adjusted accordingly.

Hyoscine Patches

  • Hyoscine patches are used off licence10 and prescribers should check the Children’s BNF before use
  • They are traditionally stuck behind the ear but work just as well on any thin, soft, hairless skin that isn’t rubbed by clothes too much, so children who pick the patches off can have them attached somewhere they are less obvious such as inside the upper arm.
  • Skin reactions to the adhesive are common and patches must be discontinued if these occur.
  • Some children get a slightly uneven dosing with the patches – too dry the first day, not enough effect by the third day. This can be overcome by changing the patches more often but a more even dosing schedule using an oral/gastrostomy preparation may be more appropriate.
  • Hysocine dose (changed every 3 days):
    • 1 month – 3 years: ¼ patch
    • 3-10 years: ½ patch
    • 10+ years: 1 patch
  • Hyoscine tablets (Kwells or JoyRides travel sickness tablets) don’t seem to be as effective as the patches and need to be taken 4 times a day.

Trihexyphenidyl hydrochloride

  • Trihexyphenidyl syrup (Broflex, benzhexol) 1mg/1ml is used off licence11 and prescribers should check the Children’s BNF before use
  • It has a blackcurrant flavour but it is not sugar free
  • Trihexyphenidyl has a convenient twice daily dosing and can be used down a gastrostomy.
  • Trihexyphenidyl dose:
    • Under 10 years consider low starting dose (1mg bd), increasing to 2mg bd as tolerated
    • Over 10 years can go as high as 3mg bd
  • It seems to be very effective for certain children and is particularly useful in children who also require medication to reduce muscle tone.
  • Morning and afternoon dosing works well for children with no night-time symptoms and allows them drug-free time overnight.

Botulinum toxin injections

Botulinum toxin injections are ideally done under local anaesthesia as their only real advantage is as a way to avoid anaesthesia and admission to hospital. If a child is undergoing surgery for any other reason (orthopaedic, dental, change of gastrostomy) then we will happily do salivary botulinum toxin injections under the same GA. Injection works well about two-thirds of the time, and when it does work it lasts about 3-4 months 12. There is a risk of dysphagia which is noticeable in about 10-15% but problematic enough to require tube feeding very rarely 12. The ideal candidate for botulinum toxin injections, then, is gastrostomy fed, and tolerant of injections due to cognitive impairment.

Action: Consider referral to the saliva control clinic when conservative measures are unsuccessful.

Surgery

For a more permanent solution, surgery may be considered. Surgery is tailored to the child’s condition and risk of aspiration. Children who do not aspirate can expect a 90% chance of an excellent result with a submandibular duct transfer 13, although it requires a few days in hospital for pain relief and a three week recovery. Submandibular gland excisions leave scars in the neck but are suitable for saliva reduction in children who are at risk of aspiration 13.

Action: Consider referral to the saliva control clinic when conservative measures are unsuccessful.

Saliva Control Clinic

The joint ENT-SLT saliva control clinic at RHC is happy to take referrals from all involved professionals. We can advise on SLT interventions, drug treatments, botulinum toxin injections and surgery.  We are also available for advice as follows:

Haytham Kubba, haytham.kubba@glasgow.ac.uk
Andrew Clement, andy.clement@nhs.scot
Susan Grosse, 
susan.grosse2@nhs.scot

Departments of Otolaryngology and Speech & Language Therapy
Royal Hospital for Children, Glasgow

Editorial Information

Last reviewed: 13/01/2025

Next review date: 31/01/2028

Author(s): Haytham Kubba, Andrew Clement, Susan Grosse.

Version: 1

Approved By: Departments of Otolaryngology and Speech & Language Therapy

Document Id: 1187

References
  1. Zeller RS, Lee HM, Cavanaugh PF et al. (2012a) Randomized phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Therapeutics and Clinical Risk Management 2012; 8: 15–23
  2. Reid S.M, et al. Anticholinergic medications for reducing drooling in children with developmental disability. Developmental Medicine & Child Neurology 2019; 63(3): 346-353.
  3. Güvenç I.A. Sialorrhea: A guide to etiology, assessment, and management. In (Ed.), Salivary Glands - New Approaches in Diagnostics and Treatment. IntechOpen 2018. https://doi.org/10.5772/intechopen.82619.
  4. Gibson N, et al. Prevention and management of respiratory disease in young people with cerebral palsy: consensus statement. Developmental Medicine & Child Neurology 2021; 63: 172-182.
  5. Gregson E, et al. Pseudomonas aeruginosa infection in respiratory samples in children with neurodisability-to treat or not to treat? Eur J Pediatr. 2021; 180(9): 2897-2905.
  6. Erasmus C.E, et al. Swallowing problems in cerebral palsy. European Journal of Pediatrics 2012; 171: 409-414.
  7. Sialanar SmPC (January 2023)
  8. BNFc https://bnfc.nice.org.uk/drugs/glycopyrronium-bromide/
  9. Parr JR, Todhunter E, Pennington L, et al. Drooling Reduction Intervention randomized trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2017; 1-6. Doi:10. 1136/ archdischild-2017-313763.
  10. GSK Scopoderm SmPC (March 2021)
  11. Rosemont Trihexyphenidyl Hydrochloride 5mg/5ml Syrup SmPC (Mar 2023)
  12. Montgomery J, McCusker S, Hendry J, Lumley E, Kubba H Botulinum toxin A for children with salivary control problems  International Journal of Pediatric Otorhinolaryngology  2014; 78(11): 1970-3
  13. Montgomery J, McCusker S, Lang K, Grosse S, Mace A, Lumley R, Kubba H. Managing children with sialorrhoea (drooling): Experience from the first 301 children in our saliva control clinic  International Journal of Pediatric Otorhinolaryngology  2016; 85: 33-9